Market Research Reports and Industry Reports

MITSUBISHI TANABE , Outperform - Invokana: Nice to Have A Clean Label, Yet A Long Way To Go Before Gaining Full Confidence!

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Invokana clean label thrills many on the street rising hopes that Invokana sales could cross $2.5b+ at peak. However we think that CV issues (dose dependent increase in LDL, CV events observed in first 30 days in CANVAS study), associated genital/UTI infections, compromised efficacy in renally impaired patients and long term safety study requirements by FDA (Table 1), should be seen in conjunction with the clean label. These issues will limit the initial uptake of Invokana to a small segment of diabetic patients - we think patients moving to triple OAD, on GLP-1 or Insulin (due to insufficient control from existing therapies, and escalating disease) are the broader target base of Invokana. Within this broader patient pool, ~40% patients with renal risks, >30% obese patients with co-morbid conditions and CV risks, and females at high UTI infection risk need to be restricted further this leaves a merely ~263k (or ~2.1% of total OAD patients) patients in the US for SGLT-2 inhibitors
Taking All Factors into Account, We arrive the Following Target Patient Base for Invokana (Table 4, 5- Invokana Market Model):.
We expect the market share to split between Invokana: Empagliflozin: Dapagliflozin by ~55:35:10 respectively as
Based on the available data comparision of Empagliflozin vs. Invokana, its efficacy looks better than Empagliflozin. While on safety front, based on PhIIb data empagliflozin reported less genital mycotic infections and equivalent UTI infection to Invokana when indirectly compared.
N/A

List Of Tables

N/A

List Of Figures

N/A

Mitsubishi Chemical Corporation - Strategic SWOT Analysis Review

Mitsubishi Chemical Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information

USD 125View Report

Mitsubishi – Laem Chabang Car Manufacturing Plant Expansion – Chonburi - Project Profile

Synopsis Mitsubishi Laem Chabang Car Manufacturing Plant Expansion Chonburi - Project Profile contains information on the scope of the project including project overview and location. The profile also details

USD 75View Report

QEWC/Mitsubishi/TEPCO/QF/QP – Umm Al Houl Integrated Power and Water Plant 2520 MW – Qatar Project Profile

Synopsis QEWC/Mitsubishi/TEPCO/QF/QP Umm Al Houl Integrated Power and Water Plant 2520 MW Qatar Project Profile contains information on the scope of the project including project overview and location. The

USD 75View Report

Mitsubishi Tanabe Pharma Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Mitsubishi Tanabe Pharma Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Mitsubishi Tanabe Pharma Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes

USD 350View Report

Mitsubishi Tanabe Partnering Deals and Alliances 2010 to 2017

The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the worlds leading life sciences companies.On demand company reports are prepared

USD 1495View Report

Mitsubishi Tanabe Pharma Corp (4508) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Mitsubishi Tanabe Pharma Corp (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, is a pharmaceutical company. The company identifies, develops, manufactures, procures and commercializes ethical drugs and over-the-counter (OTC)

USD 250View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 500
  • Site Licence    USD 1000
  • Enterprisewide Licence    USD 1500
$ 500

Reports Details

Published Date : Apr 2013
No. of Pages :9
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube
paykasa bozdurma,paykasa bozdurma,astropay bozdurma,paykasa,paykasa,paykasa bozdurma,paykasa,astropay bozdurma,justin kart,bitcoin bozdurma,paykasa bozum,paykasa kart bozdurma,
beylikduzu escort,bahçeşehir escort,escort istanbul,istanbul escort,sex hikayeleri,pendik escort,
pedalebiellese.com,
istanbul escort bayan,besiktas escort,maltepe escort,kadikoy escort bayan,tekirdag escort bayan,findikzade escort,antalya escort bayan,ankara escort bayan,
Böcek İlaçlama,şehirler arası nakliyat,şehirler arası evden eve nakliyat,ofis taşıma,gebze evden eve nakliyat,kadıköy evden eve nakliyat,istanbul evden eve nakliyat,epoksi zemin,
ankara escort,ankara escort,ankara escort,
tipobet,
seo teknikleri wordpress ücretsiz tema istanbul sexs shop hacklink e sigara sexs shop